a pill with no food restrictions and no cold chain changes this entire site
Flairing this Speculation because that is what it is.
Orforglipron is a small molecule, not a peptide. ATTAIN-1 and ACHIEVE-1 (both NEJM, 2025) reported the efficacy numbers everyone quotes, but the interesting property is not the percentage. It is that a non-peptide oral escapes the absorption problem that makes oral semaglutide a 50mg-with-water-and-wait proposition, and it does not need a fridge.
Think about what that removes: reconstitution math, cold chain, excursion anxiety, lyophilised-versus-solution, half of c/coldchain and a good chunk of c/reconstitution. Purity testing becomes a different problem — small-molecule assay rather than peptide chromatography.
Not saying this happens soon. Saying that if it happens, this site looks structurally different.
best — the order this archive was captured in
The analytical half of this is a bigger change than people assume. Small-molecule purity work has different failure modes — you are looking for process impurities and degradants with well-defined structures rather than truncations and deamidations across a 30-residue chain.
It is also, generally, easier and cheaper to characterise. Which cuts both ways: easier for legitimate suppliers and easier for anyone generating a plausible-looking document.
i had not thought about the forgery side. a simpler assay is a simpler thing to fake convincingly.
and the community has three years of pattern-matching built on peptide documents. we would be starting again on the tells.
the nine patterns are mostly about documents and behaviour rather than chemistry, so i think most of them port. the chemistry-specific ones would not.
fair. the recycled-COA and generated-social-proof patterns are chemistry-agnostic.
i would be delighted to be made obsolete and i do not believe i will be. even in that world somebody is shipping something to somebody at the wrong temperature.
the availability question is the one to keep flaired as speculation. an approved oral and an accessible oral are different things and this community knows that better than most.
from a UK pricing perspective an oral changes the private-prescription market more than the NHS one. edit: probably. everything about UK access surprises me eventually.
speculating about a drug that is not on the market is exactly the content this site claims not to do
Speculation flair exists precisely so this content can be here and be labelled. The rule is not "no speculation", it is "no speculation dressed as findings".
- 1The analytical half of this is a bigger change than people assume.…5 comments in this branch · started by u/sig_figs_sam